A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

← catalyst calendar

NCT07215975 · readout in 1,289 d

Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

200estimated

Sites

Countries

Kuwait, Oman, Saudi Arabia +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-26

actual

When the study began enrolling

Primary completion

2030-02-28

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-04-17

estimated

The whole study's end, after follow-up

First posted

2025-10-14

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-19

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

β-thalassemia

Intervention

Drug: Luspatercept

Primary outcomes

what the primary-completion date above is the date OF

Change in transfusion burden

measured Baseline and up to week 144

Change in mean pre-transfusion hemoglobin level

measured Baseline and up to week 144

Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed